Wyeth Articles
USA's Top-Selling Drugs In 1993
24 October 1994
Generics To Lead US Managed Care "Soon"
17 October 1994
Effexor Superior To Prozac?
10 October 1994
Etodolac Comarketing Agreement
3 October 1994
Wyeth-Ayerst To Take Annuelle Into Ph III
26 September 1994
Azapropazone Should Be Last Choice NSAID Says CSM
12 September 1994
FDA, HHS Probe Pharmacy Promos
5 September 1994
AHP Bid For Cyanamid Will Broaden Product Range
15 August 1994
Small US Companies On Target At Half Year
15 August 1994
Interleukin-12 Research Alliance Founded
1 August 1994
NORPLANT PROBLEMS
25 July 1994
Norplant Lawsuit To Expand Focus
18 July 1994
WYETH APPOINTMENT
13 June 1994
AHP CONSOLIDATION EFFECTS
30 May 1994
NEW HORIZONS FOR THE USE OF LMW HEPARIN
30 May 1994
US FDA APPROVES NEW GENERICS
16 May 1994
JEFFREY BOILY
9 May 1994
WEST POINT EXPANDS PRODUCT LINE
9 May 1994
WYETH-AYERST APPOINTMENT
2 May 1994
STERLING WINTHROP GENERICS ARM
25 April 1994
NEW PLAYER IN US DEPRESSION MARKET
25 April 1994
B-MS LAUNCH IN USA
28 March 1994
US CONTRACEPTIVE PRICING SLAMMED
28 March 1994
ROBERT LEVY
7 March 1994
NORPLANT TOO EXPENSIVE FOR POOR IN USA
21 February 1994
PENTAGON ABANDONS AIDS VACCINE TRIALS
7 February 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
FRAGMIN APPROVABLE, SAYS FDA
24 January 1994
WYETH TO END VAXSYN DEAL
24 January 1994
WORLD PRODUCT NEWS IN BRIEF
24 January 1994
NEW APPROVALS CHANGE DEPRESSION MARKET
17 January 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
NORMIFLO REJECTED BY FDA
20 December 1993
ANALYSTS FORECAST FDA YEAR-END APPROVALS
13 December 1993
WYETH SLATED OVER NORPLANT PRICE
13 December 1993
EFFEXOR APPROVABLE FOR DEPRESSION
22 November 1993
ANANXYL WITHDRAWN FROM MARKET IN FRANCE
1 November 1993
CHANGES AT AHP
27 September 1993
ONLY MICROGENESYS VACCINE TO BE TESTED
6 September 1993
LODINE IN HIGHER STRENGTH
23 August 1993
SEARLE HALTS MAXAQUIN COPROMOTION
9 August 1993
WYETH-AYERST APPOINTMENT
12 July 1993
STRONG GROWTH AT PROFARMA IN CHILE
12 July 1993
CONFUSING SITUATION ON PATENTS IN VENEZUELA
5 July 1993
R&D INVESTMENTS BY US GENERICS MAKERS
28 June 1993
OPPORTUNITIES IN UK BIOSCIENCE SECTOR
21 June 1993
BRAZILIAN DRUG PROFITS TO BE INVESTIGATED
24 May 1993
WYETH-AYERST APPOINTMENT
17 May 1993
WYETH-AYERST WIDENS GENERIC LINE
17 May 1993
FDA PANEL BACKS EFFEXOR
10 May 1993
ELI LILLY'S RALOXIFENE: PHASE II RESULTS
26 April 1993
DRUG COMPANIES LOOK TO MEXICO
26 April 1993
AYERST RESHUFFLES IN CANADIAN MERGER
19 April 1993
MICROGENESYS AIDS VACCINE IN TROUBLE?
5 April 1993
NEW AHP PRESIDENT
15 March 1993
PHAP APPOINTMENTS
22 February 1993
ENZYME IMPLANT FOR LIPID-LOWERING
15 February 1993
OVRAL RESEARCH
8 February 1993
WYETH TO GET DUTCH MOH COMPENSATION
1 February 1993
BENZODIAZEPINE LITIGATION
1 February 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
NORPLANT PURCHASED BY US GOVERNMENT
25 January 1993
UK BLACKLIST and a "TWO-TIER" NHS
18 January 1993
UK INDUSTRY PROTEST OVER NHS LIST PLANS
4 January 1993
1992 SEES SMALLER COMPANY MERGERS
4 January 1993
AMERICAN HOME: FINALLY A PHARMA COMPANY
7 December 1992
FDA APPRO FOR SEARLE'S DAYPRO
9 November 1992
SHIFTS FORECAST IN US CONTRACEPTIVES MARKET
3 August 1992
SEARLE'S MAXAQUIN
29 June 1992
WELLCOME LOOKING TO OTC ZOVIRAX
29 June 1992
US FDA ABANDONS COMPANY ALERT LIST
29 June 1992
THE CHANGING MARKET FOR HERBAL MEDICINES
29 June 1992
WYETH LOSES ROUND IN GENERICS BATTLE
15 June 1992
Maxaquin to be copromoted
8 June 1992
COPROMOTION DEAL FOR ZOVIRAX IN USA
8 June 1992
HORMONE REPLACEMENT THERAPY: US REPORT
8 June 1992
TLC CHAIRMAN LOOKS BACK ON 1991
18 May 1992
NOSE DROP FLU VACCINE
11 May 1992
AMERICAN HOME TO BUY SERONO UNITS
27 April 1992
APPOINTMENTS IN WYETH-AYERST GROUP
20 April 1992
US NEW PRESCRIPTI0N DRUG SALES IN 1991
13 April 1992
PROMISING ALZHEIMER'S PROGRAM FROM ATHENA
13 April 1992
DEPRESSION: THE COST TO SOCIETY
6 April 1992
1991 OUTSTANDING YEAR FOR AMERICAN HOME
6 April 1992
AMA REPORT ON CONTRACEPTIVES
6 April 1992
AMA REPORT ON CONTRACEPTIVES
6 April 1992
1991 OUTSTANDING YEAR FOR AMERICAN HOME
6 April 1992
DEPRESSION: THE COST TO SOCIETY
6 April 1992
GI/AHP SMALL MOLECULE AGREE'T
16 March 1992
APPOINTMENTS AT SANDOZ
16 March 1992
WYETH LTD/LTEE: SEAN FLYNN
16 March 1992
US GENERIC DRUG MARKET TO 1995
17 February 1992
WYETH AYERST/ TLC FLU VACCINE DEAL
3 February 1992
FRANCE LOWERS ORAL CONTRACEPTIVE PRICES
13 January 1992
SYNTEX' ORAL TORADOL APPROVED IN USA
13 January 1992
ANALGESICS IN THE USA -- AN OPEN DOOR FOR P&G?
6 January 1992
ROBERTS TO ACQUIRE WYETH LABS DRUGS
6 January 1992
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
